Monopar Therapeutics (MNPR) Enterprise Value (2016 - 2025)

Monopar Therapeutics has disclosed Enterprise Value across 10 years of filings, most recently posting -$61.8 million for Q4 2025.

• Enterprise Value for Q4 2025 came in at -$61.8 million, down 34.96% year-over-year; the trailing twelve-month figure through Dec 2025 was -$61.8 million (down 34.96% YoY), and the FY2025 annual result was -$61.8 million, down 34.96% from the prior year.
• Enterprise Value came in at -$61.8 million for Q4 2025 at Monopar Therapeutics, up from -$127.7 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$5.5 million in Q3 2023 to a low of -$127.7 million in Q3 2025.
• The 5-year median for Enterprise Value is -$17.1 million (2022), against an average of -$25.4 million.
• Across the five-year window, Enterprise Value jumped 67.87% in 2023 and sank 2020.86% in 2025, its largest moves.
• Monopar Therapeutics' Enterprise Value stood at -$20.0 million in 2021, then jumped by 59.1% to -$8.2 million in 2022, then climbed by 11.24% to -$7.3 million in 2023, then slumped by 530.55% to -$45.8 million in 2024, then plunged by 34.96% to -$61.8 million in 2025.
• The last three Enterprise Value figures came in at -$61.8 million (Q4 2025), -$127.7 million (Q3 2025), and -$39.5 million (Q2 2025), per Business Quant data.